跳转至内容
Merck
CN

PHR1624

顺铂

Pharmaceutical Secondary Standard; Certified Reference Material

别名:

顺铂, 顺-二氯二氨基铂(II), 顺式-二胺二氯铂, 顺氯氨铂

登录 查看组织和合同定价。

选择尺寸

关于此项目

线性分子式:
Pt(NH3)2Cl2
化学文摘社编号:
15663-27-1
分子量:
300.05
NACRES:
NA.24
PubChem Substance ID:
329823516
UNSPSC Code:
41116107
EC Number:
239-733-8
MDL number:
MFCD00011623

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

顺铂, Pharmaceutical Secondary Standard; Certified Reference Material

InChI key

LXZZYRPGZAFOLE-UHFFFAOYSA-L

InChI

1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2

SMILES string

N.N.Cl[Pt]Cl

grade

certified reference material
pharmaceutical secondary standard

agency

traceable to Ph. Eur. C2210000
traceable to USP 1134357

API family

cisplatin

CofA

current certificate can be downloaded

packaging

pkg of 200 mg

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

mp

270 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-30°C

Quality Level

300

正在寻找类似产品? 访问 产品对比指南

相关类别

Analysis Note

这些二级标准提供了有效的美国药典、欧洲药典和英国药典一级标准的多重可追溯性。

Application

这些二级标准品是经过检验的认证标准物质(CRM)。它们适用于多种分析应用，包括但不限于药物释放测试、药物的定性和定量分析方法开发、食品和饮料质量控制检测以及其他校准需求。
顺铂可用作分析参考标准品，通过高效液相色谱测定法测定血浆、癌细胞和肿瘤样品中的分析物。

Biochem/physiol Actions

强效的铂基抗肿瘤剂。与 DNA 二核苷酸 d(pGpG) 形成细胞毒性加合物，诱导链内交联。

General description

用于质量控制的制药二级标准品，为制药实验室和制造商制备内部工作标准品提供了一种方便、高性价比的替代方案。
顺铂是抗肿瘤药，用于治疗各种恶性肿瘤患者。

Other Notes

要查看该材料的分析证书示例，请在下面的栏位中输入LRAB7778。这只是一个示例证书，可能不是您收到的批次。
该认证参考物质（CRM）根据ISO 17034 和 ISO/IEC 17025进行生产和认证。有关此CRM使用的所有信息均可在分析证书上找到。

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

Hazard Classifications

Acute Tox. 2 Oral - Carc. 1B - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

target_organs

Respiratory system

存储类别

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Sonja Ludwig et al.
Cancer immunology, immunotherapy : CII, 68(7), 1133-1141 (2019-05-30)
Advanced oral squamous cell carcinomas (OSCC) have limited therapeutic options. Although immune therapies are emerging as a potentially effective alternative or adjunct to chemotherapies, the therapeutic efficacy of combination immune chemotherapies has yet to be determined. Using a 4-nitroquinolone-N-oxide (4NQO)
A high-performance liquid chromatographic assay for determination of cisplatin in plasma, cancer cell, and tumor samples.
Lopez-Flores A, et al.
Journal of Pharmacological and Toxicological Methods, 52(3), 366-372 (2005)
Sample handling for determination of free platinum in blood after cisplatin exposure.
Johnsson A, et al.
Cancer Chemotherapy and Pharmacology, 41(3), 248-251 (1997)
Jessica M Rusert et al.
Cancer research, 80(23), 5393-5407 (2020-10-14)
Medulloblastoma is among the most common malignant brain tumors in children. Recent studies have identified at least four subgroups of the disease that differ in terms of molecular characteristics and patient outcomes. Despite this heterogeneity, most patients with medulloblastoma receive
Adrián E Granada et al.
Molecular biology of the cell, 31(8), 845-857 (2020-02-13)
DNA-damaging chemotherapeutics are widely used in cancer treatments, but for solid tumors they often leave a residual tumor-cell population. Here we investigated how cellular states might affect the response of individual cells in a clonal population to cisplatin, a DNA-damaging
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持